title: Raltegravir central nervous system tolerability in clinical practice:  results from a multicenter observational study.
abstract: Central nervous system (CNS) symptoms have been reported in clinical trials and case reports in patients receiving raltegravir. We investigated CNS symptoms in 453 HIV-infected patients. Of these 47 (10.4%) developed at least one drug-related CNS symptom. Predictors of CNS symptoms were concomitant therapy with tenofovir or with proton pump inhibitors that can increase raltegravir concentration. Thus, our data suggest a possible correlation between high raltegravir plasma concentrations and CNS symptoms, and therefore their monitoring in clinical practice.
authors.affiliation: Department of Clinical and Experimental Medicine, University of Sassari, Italy. giordano.madeddu@uniss.it
authors.forename: Giordano
authors.initials: G
authors.lastname: Madeddu
authors.forename: Barbara
authors.initials: B
authors.lastname: Menzaghi
authors.forename: Elena
authors.initials: E
authors.lastname: Ricci
authors.forename: Laura
authors.initials: L
authors.lastname: Carenzi
authors.forename: Canio
authors.initials: C
authors.lastname: Martinelli
authors.forename: Antonio
authors.initials: A
authors.lastname: di Biagio
authors.forename: Giustino
authors.initials: G
authors.lastname: Parruti
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Orofino
authors.forename: Maria S
authors.initials: MS
authors.lastname: Mura
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonfanti
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D002490:Central Nervous System / Q000187:drug effects* / Q000503:physiopathology; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects / Q000097:blood; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D000225:Adenine